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Background. Respiratory syncytial virus (RSV) is among the most important causes of acute lower respiratory tract infection 
(ALRI) in young children. We assessed the severity of RSV-ALRI in children less than 5 years old with bronchopulmonary dysplasia 
(BPD).
Methods. We searched for studies using EMBASE, Global Health, and MEDLINE. We assessed hospitalization risk, intensive 
care unit (ICU) admission, need for oxygen supplementation and mechanical ventilation, and in-hospital case fatality (hCFR) among 
children with BPD compared with those without (non-BPD). We compared the (1) length of hospital stay (LOS) and (2) duration of 
oxygen supplementation and mechanical ventilation between the groups.
Results. Twenty-nine studies fulfilled our inclusion criteria. The case definition for BPD varied substantially in the included 
studies. Risks were higher among children with BPD compared with non-BPD: RSV hospitalization (odds ratio [OR], 2.6; 95% 
confidence interval [CI], 1.7–4.2; P < .001), ICU admission (OR, 2.9; 95% CI, 2.3–3.5; P < .001), need for oxygen supplementation 
(OR, 4.2; 95% CI, .5–33.7; P = .175) and mechanical ventilation (OR, 8.2; 95% CI, 7.6–8.9; P < .001), and hCFR (OR, 12.8; 95% CI, 
9.4–17.3; P < .001). Median LOS (range) was 7.2 days (4–23) (BPD) compared with 2.5 days (1–30) (non-BPD). Median duration of 
oxygen supplementation (range) was 5.5 days (0–21) (BPD) compared with 2.0 days (0–26) (non-BPD). The duration of mechan-
ical ventilation was more often longer (>6 days) in those with BPD compared with non-BPD (OR, 11.9; 95% CI, 1.4–100; P = .02).
Conclusions. The risk of severe RSV disease is considerably higher among children with BPD. There is an urgent need to estab-
lish standardized BPD case definitions, review the RSV prophylaxis guidelines, and encourage more specific studies on RSV infec-
tion in BPD patients, including vaccine development and RSV-specific treatment.
Keywords.  acute lower respiratory infections; bronchopulmonary dysplasia; chronic lung disease; respiratory syncytial virus.
Respiratory syncytial virus (RSV) is among the leading causes 
of acute lower respiratory tract infection (ALRI) in children, 
with an increased risk of severe RSV-ALRI in children with 
comorbidities such as bronchopulmonary dysplasia (BPD) [1]. 
Bronchopulmonary dysplasia is strongly linked with prema-
turity; with the increase in the viability of premature infants 
due to the advancements in neonatal medicine, 15%–50% of 
these children will be affected by BPD [2]. Approved RSV an-
tiviral treatments are lacking, and prevention of RSV-ALRI is 
currently limited to infection control measures and postnatal 
prophylaxis with palivizumab [3]. However, there is promising 
research progress in the development of an RSV vaccine, with 
16 candidate vaccines/monoclonal antibodies currently at var-
ious phases of clinical trials [4].
There has been a growing recognition of RSV-ALRI disease 
burden, for example, Paes et al [1] showed a significant associa-
tion between BPD and RSV-ALRI hospitalization, an increased 
risk of prolonged hospitalization, and a greater requirement 
for medical support. However, a meta-analysis of published 
data on RSV-ALRI disease severity among infants with BPD 
is lacking. We performed a systematic review of studies and a 
meta-analysis on available data regarding RSV-ALRI hospital-
ization, intensive care unit (ICU) admission, need for oxygen 
supplementation and mechanical ventilation, and in-hospital 
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case fatality ratio (hCFR) among children with BPD compared 
with those without (non-BPD).
METHODS
Study Search and Selection
P.S.C.  and L.H.  independently conducted a systematic search 
for studies using EMBASE, Global Health, and MEDLINE 
(Supplementary Table 1), completed on April 4, 2017. We 
selected the relevant studies following the PRISMA pro-
tocol (http://www.prisma-statement.org/PRISMAStatement/
FlowDiagram). Where discrepancies existed, the 2 researchers 
discussed to reach a consensus. Restriction was only based 
on the language of publication (English and French). The re-
view was registered on PROSPERO, registration number 
CRD42018090848 (https://www.crd.york.ac.uk/prospero/).
Outcomes of Interest
The population of interest is children less than 5 years old, the 
exposure is a diagnosis of BPD, and the comparator group are 
those without (non-BPD). We assumed all children not diag-
nosed with BPD as “non-BPD”. Where specified, we conducted 
subgroup analysis based on gestation age and existence of co-
morbidity. Our outcomes of interest were RSV associated hos-
pitalizations, length of hospital stay (LOS), admissions to and 
length of stay in the intensive care unit (ICU) (LOS-ICU), need 
for and duration of oxygen supplementation, need for and du-
ration of mechanical ventilation, and hCFR. We considered all 
the cases referred to as chronic lung disease as BPD, excluding 
other conditions such as asthma and cystic fibrosis. For an in-
terventional study, we used the placebo arm to extract the re-
quired data.
Inclusion and Exclusion Criteria
We included the following: any published study that reported 
data on RSV-associated ALRI hospitalizations among children 
aged less than 5 years with BPD and non-BPD; studies that as-
sessed ALRIs hospitalizations specifically due to RSV rather 
than as a coinfection; studies that specifically assessed BPD as 
an underlying disease rather than as a comorbidity; studies that 
assessed the use of immunotherapy with specific data on our 
outcomes of interest in the placebo group; and studies that did 
not specify use of prophylaxis or regarded prophylaxis as not 
appropriate. We excluded studies that included children with 
unspecified age or ≥5  years old without relevant data for the 
under-5-year-old subgroup.
Data Extraction and Synthesis
P.S.C.  and L.H.  independently extracted all available data on 
the outcomes of interest using a standard Microsoft Excel 2000 
spreadsheet. We modified the GRADE scoring system to eval-
uate the quality of the included studies [5] (Supplementary 
Table 2). We used Stata version 12 (Stata Corp., College Station, 
TX) to analyze the data and applied odds ratio (OR) to com-
pare risk for RSV-ALRI among BPD group for hospitalization, 
ICU admission, oxygen supplementation, mechanical ventila-
tion, and hCFR; and rate ratio for hospitalization rate in com-
parison to non-BPD. We performed a stratified analysis where 
feasible. We used the most widely accepted definition of BPD as 
the “requirement for any respiratory support at 36 weeks cor-
rected gestation” [6], and we defined prematurity as gestational 
age (GA) of ≤36 weeks, as implied in our BPD definition. When 
a study provided separate data for different GAs, we extracted 
data for BPD and non-BPD and conducted the meta-analysis 
based on GA. When meta-analysis was not feasible, we reported 
the proportions, mean, median, and the measures of risk as pro-
vided by any single study. We calculated the risk from the data 
in the original articles when the measures of risk were not pro-
vided. We used Egger’s test to assess publication bias (https://
www.bmj.com/content/346/bmj.f1342). Where applicable, we 
used the 95% confidence interval (CI). We set the statistical sig-
nificance at <0.05.
RESULTS
Study Characteristics and Population
Twenty-nine studies fulfilled our inclusion criteria 
(Supplementary Figure 1 and Supplementary Tables 4 and 5). 
There was substantial heterogeneity in the case definition for 
BPD among included studies (Supplementary Table 4). The 
overall quality of the studies was moderate (average score of 
3.4): 25 were of moderate quality, and 4 were of low quality 
(Supplementary Table 3). Outcomes with significant heteroge-
neity were hospitalization rate (I2 = 97.1%, P < .001) (Figure 2) 
and proportion of episodes associated with hospitalization 
(I2 = 93.6%, P < .001) (Figure 1). There was no evidence of pub-
lication bias in any of the measured outcomes where the test 
was feasible: risk of hospitalization (P = .200), ICU admission 
(P = .301), mechanical ventilation (0.950), and hCFR (P = .836).
Hospitalization and Length of Hospital Stay
Two studies reported RSV hospitalization rate among children 
with BPD and non-BPD. Mean hospitalization rate was 
186.4/1000 person-years for BPD and 13.3/1000 person-years 
for non-BPD (incidence rate ratio [IRR]), 20.0; 95% CI, 10.0–
39.8; P  <  .001) (Supplementary Figure 2). Respiratory syncy-
tial virus hospitalization rate and IRR were age dependent: 
412.9/1000 person-years for BPD, 33.6/1000 person-years for 
non-BPD (IRR, 9.9; 95% CI, 4.9–20.0; P  <  .001) in children 
less than 12  months old; 121.8/1000 person-years for BPD, 
5.1/1000 person-years for non-BPD (IRR, 24.5; 95% CI, 13.8–
43.4; P < .001) in children aged 12 to 24 months; and 24.4/1000 
person-years for BPD, 1.2/1000 person-years for non-BPD 
(IRR, 35.8; 95% CI, 4.9–264.0; P < .001) in children aged older 
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Fourteen studies reported the risk of RSV hospitalizations 
[6–19]: 16.8% in BPD and 9.1% in non-BPD (OR, 2.6; 95% CI, 
1.7–4.2; P < .001) (Figure 1). Within the prematurity subgroup, 
BPD was 15.2% versus non-BPD at 9.2%: OR = 2.2 (95% CI, 
1.2–4.1; P = .013) (in overall premature group), OR = 1.9 (95% 
CI, .9–4.0; P = .104) (≤35 weeks GA), and OR = 2.6 (95% CI, 
1.0–7.2; P = .062) (≤33 weeks GA).
By World Bank income regions, RSV hospitalization was 
17.8% for BPD and 6.7% for non-BPD from high-income coun-
tries [6, 8–12, 15, 17–20] (OR, 3.3; 95% CI, 2.0 – 5.7; P < .001) 
and 13.7% for BPD and 13.6% for non-BPD from upper-
middle-income countries (OR, 1.2; 95% CI, .4–3.8; P  =  .710) 
(Supplementary Figure 3). The difference between the 2 groups 
was not significant (P = .100).
In addition, in adjusted multivariable analyses, studies re-
ported higher odds for risk of RSV hospitalization for BPD 
versus non-BPD (Supplementary Figure 4). Two studies only 
provided data on the risk during a specific period: Rietveld et al 
[21] reported a 10.4% hospitalization risk in the first year of 
life for BPD and 7.5% for non-BPD (OR, 1.4; 95% CI, 1.0–2.0; 
P = .047; GA unspecified). Weigl et al [22] reported a 17.8-fold 
increased risk of hospitalization for RSV in children less than 
2 years old with BPD (95% CI, 1.7–188.0) compared with non-
BPD (GA of <32 weeks for both groups).




Overall  (I-squared = 93.6%, p = 0.000)
Kanra et al. [14]
IMPACT Study Group [10]
Study
Boyce et al. [8]
Lee et al. [16]
Homaira et al. [12]
Redding et al. [18]
PREVENT Study Group [11]
Other possible co-morbidities not specified(a)
Subtotal  (I-squared = 97.9%, p = 0.000)
Premature birth
Berner et al. [7]
Hsu et al. [13]
Thomas et al. [19]
Hong et al. [6]
Co-morbidities studied excluded(b)
Lacaze-Masmontel et al. [15]
Liese et al. [17]
Carbonell-Estrany et al.[9]
Subtotal  (I-squared = 85.9%, p = 0.000)
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Odds Ratio
Figure 1. Risk of respiratory syncytial virus (RSV)-associated hospitalization in children with bronchopulmonary dysplasia (BPD) versus those without BPD (odds ratios [ORs] 
and corresponding confidence intervals based on proportions of RSV hospitalization among BPD and non-BPD). Comorbidities studied: BPD; congenital heart disease, other 
than patent ductus arteriosus or a septal defect. aOther possible comorbidities not specified: these studies provided data for children without BPD as comparison group, other 
possible underlying diseases other than BPD were not specifically excluded. bComorbidities studied excluded: these studies provided specific data for children without BPD 
and other underlying diseases other than BPD as comparison group (Hsu et al [13] reported this as children born at 37 weeks gestational age (GA) without BPD; congenital 
heart disease, other than patent ductus arteriosus, or a septal defect that was hemodynamically insignificant; or any congenital anomaly. Boyce et al [8] reported this as 
“low risk” children). I-squared: the variation in OR due to for heterogeneity. Subgroup analysis for the prematurity subgroup based on GA was excluded from the figure due 
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Intensive Care Unit (ICU) Admission and Length of ICU Stay
We obtained the proportion of ICU admissions due to RSV 
among BPD (17.2%) versus non-BPD (6.8%) (OR, 2.9; 95% 
CI, 2.3–3.5; P < .001) from 4 studies (Supplementary Figure 
5). Two studies reported the proportion of RSV-associated 
hospitalizations that required ICU admission as 12.0% 
(BPD-RSV) and 4.0% (non-BPD-RSV with comorbidities 
excluded) (OR, 3.0; 95% CI, .4–20.7; P < .258; GA unspec-
ified) [23, 24].
Oxygen Supplementation and Mechanical Ventilation
Two studies provided data on BPD versus non-BPD that needed 
oxygen supplementation. Oxygen supplementation was re-
quired by 80% of BPD and 65% of non-BPD (OR, 4.2; 95% CI, 
.5–33.7; P = .175) [24, 25].
Four studies provided the proportion of BPD versus non-
BPD that required mechanical ventilation (GA unspecified): 2 
reported 24.0% for BPD versus 19.0% for non-BPD (OR, 1.1; 
95% CI, .5–2.4; P = .874) [26, 27]; 2 reported 24.0% for BPD 
versus 4.0% for non-BPD and other underlying diseases ex-
cluded (OR, 8.2; 95% CI, 7.6–8.9; P < .001) [24, 27]. Borckink 
et al [28] reported that BPD children had an increased prob-
ability of needing mechanical ventilation (hazard ratio, 3.5; 
95% CI, 1.1–11.9; P = .04).
The reported LOS, LOS-ICU, and duration of oxygen sup-
plementation and mechanical ventilation in the 2 groups are 
heterogeneous (Supplementary Table 7). In addition, Zhang 
et al [29] provided data on severe RSV-ALRI based on clin-
ical signs, defined as children with RSV-ALRI with apnea in 
the hospital, pH <7.35, pCO2 >45 mmHg, arterial sO2 <87%, 
LOS >5  days, and if mechanical ventilation was required. 
In their study, the BPD group had a 12.4-fold higher risk of 
severe disease (95% CI, 2.7–56.2; P  =  .001) compared with 
non-BPD.
NOTE: Weights are from random eects analysis
.
.
Overall  (I-squared = 0.0%, p = 0.430)
Berger et al. [20]
Co-morbidities studied excluded(b)
Vizcarra-Ugalde et al. [23]
Doucette et al. [27]
Buckingham et al. [26]
Other possible co-morbidities not specified(a)
Duppenthaler et al. [24]
Berner et al. [7]
Study
Subtotal  (I-squared = 47.5%, p = 0.126)
Lacaze-Masmontel et al.  [15]
























Favors Control Favors BPD 
1.1 20
Odds Ratio
Figure 2. Risk of respiratory syncytial virus (RSV)-associated deaths in children with bronchopulmonary dysplasia (BPD) versus those without BPD and with or without 
other comorbidities (odds ratios [ORs] and corresponding confidence intervals based on proportion of children with BPD and non-BPD who died during hospitalization). aOther 
possible comorbidities not specified: these studies provided data for children without BPD as comparison group, other possible underlying diseases other than BPD were 
not specifically excluded. bComorbidities studied excluded: these studies provided specific data for children without BPD and other underlying diseases other than BPD as 
comparison group (Vizcarra-Ugalde et al [23] reported this as “children without underlying medical conditions.” Doucette et al reported this as “non-high risk” children. 
Buckingham et al [26] reported this as “non-CLD, non-CHD, non-Upper airway abnormalities, and no other non-cardiac congenital malformations” children. Duppenthaler et al 
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In-Hospital Case Fatality Ratio
We obtained the hCFR for RSV-ALRI among BPD and non-
BPD from 7 studies, with a proportion of 4.4% and 0.2%, re-
spectively (OR, 12.8; 95% CI, 9.4–17.3; P < .001) (Figure 2). Prill 
et al [30] reported a total registered RSV-associated mortalities 
of 26 (RSV positive) among children <2  years old, 6 (23.1%) 
with BPD, 5 (19.2%) with low risk (GA unspecified), and the 
rest had other risk factors.
DISCUSSION
We have demonstrated that the risk of severe RSV-ALRI, de-
fined by the measured outcomes, was higher among BPD 
compared with non-BPD. The LOS, LOS-ICU, and duration 
of oxygen supplementation and mechanical ventilation were 
longer among BPD compared with non-BPD, also suggesting a 
more severe disease among the former.
Overall hospitalization rate was approximately 20-fold 
higher among the BPD than the non-BPD. Our results show 
that the RSV-associated hospitalization rates tend to decrease 
with age, especially after 24 months of the age as reported previ-
ously [22]. However, the rate of decline was higher among non-
BPD than BPD, thus leading to the wider difference in rates and 
higher odds as the children got older. The ORs for RSV hospi-
talization among BPD compared with non-BPD were higher in 
high-income countries compared with upper-middle-income 
countries. This may have been partly due to the higher disease 
burden and therefore a higher proportion of hospitalizations 
among the non-BPD group in upper-middle-income countries. 
However, the proportion of hospitalizations for BPD remained 
high in high-income countries, even higher than in the upper-
middle-income countries. This suggests the need for control 
measures even in developed countries where a cost effective-
ness of immunotherapy prophylaxis compared with treatment 
of severe RSV disease for children with BPD has already been 
shown [31]. Hospitalization risks were inversely proportional to 
GA of the children, suggesting a more severe disease outcome 
the lower the GA.
Both LOS and LOS-ICU were longer among BPD compared 
with non-BPD. Hong et  al [6] reported a slightly longer LOS 
for BPD without use of home oxygen (7.2; interquartile range 
[IQR], 3.2–11.2) compared with BPD using home oxygen (7.0; 
IQR, 4.2–12.8), probably due to longer waiting time for doc-
tors to discharge patients who may have needed oxygen during 
admission until when they no longer need it, compared with 
those who can continue on their oxygen need at home upon 
discharge. The high odds of need for oxygen supplementation 
in BPD demonstrate the increase in the dependency of the 
BPD cases on oxygen following RSV-ALRI. Respiratory syn-
cytial virus-ALRI worsens the already underfunctioning lung 
in BPD, increasing the need for ventilation support [32], thus 
many of the hospitalized children may have ended up in an ICU 
where additional ventilation support can be accessed. There is 
also an increased risk of long-term disease complications and 
disabilities further affecting child wellbeing including a decline 
in lung function with age [32]. Therefore, severe RSV disease 
in children with risk factors such as BPD will not only lead to 
a longer hospital stay, but also to a higher need for long-term 
follow up and management, and thus incur significantly higher 
costs of treatment. Therefore, interventional measures to pre-
vent RSV infections are useful and should be made available 
and affordable.
Immunoprophylaxis (using palivizumab) has been shown 
to have a high efficacy for preventing severe RSV disease and 
a lower cost compared with treatment of the acute condition 
[31]. However, their availability and application remains a 
problem and maybe one of the reasons why RSV disease still 
remains severe in certain settings. Although current guidelines 
recommend its use for BPD, it is mainly limited for children 
under 24 months old, probably due to the higher incidence of 
RSV infections in this age group. A  group of experts, mainly 
in pediatric cardiology, provided an updated guideline for 
immunoprophylaxis use [33]. Among the countries included, 
only Canada and the United States indicated BPD on the list 
of underlying diseases requiring immunoprophylaxis, and 
only Canada provided precise indications as “children aged 
<12 months with BPD, requiring ongoing diuretics, broncho-
dilators, steroids, or supplemental oxygen, at the start of RSV 
season” and “children aged <24 months who are on home ox-
ygen, with prolonged hospitalization for pulmonary disease or 
severely immunocompromised”. The RSV-associated hospitali-
zation rates tend to decrease with age, especially after 24 months 
of the age, as reported previously [22]. However, although there 
were limited data from only 2 studies to make any definitive 
conclusion, our study has shown that despite a lower hospi-
talization rate in the older group (with a higher rate of decline 
among non-BPD than BPD as highlighted above), the odds for 
RSV hospitalization tend to be higher as the child grows older, 
suggesting a more severe disease among the BPD cases, possibly 
explained by the persistent pulmonary dysfunction and the 
worsening ventilation perfusion mismatch [34] in the presence 
of an increasing body activity and requirement for oxygen use 
as the child grows older. Therefore, immunoprophylaxis could 
have a great impact on older children despite the lower hospi-
talization rates. Considering that the current definition of BPD 
is a spectrum, defining BPD as mild, moderate, or severe and 
assessing the oxygen requirement with time for those on home 
oxygen maybe useful.
The high cost of palivizumab or biosimilars in development 
and the high number needed to treat to prevent hospitalization 
could be reasons that limit their use. Because the cost limitation 
may more seriously affect low-income countries, where RSV 
disease incidence is reported to be higher compared with higher 
income countries [35], a success in the current progress on the 
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preventing severe RSV disease among high-risk groups when 
made affordable. Our results show a consistency and a strong 
positive association between BPD and all outcomes included in 
the meta-analysis, suggesting a strong positive association be-
tween BPD and severe RSV-ALRI disease.
Strengths and Limitations
The review provides up-to-date data on the association be-
tween BPD and RSV-ALRI disease severity. It provides useful 
information from individual studies and combined effects from 
different studies through meta-analysis. Sensitivity analysis 
provides additional information where differences may exist 
and where focus for interventional measures will be useful. 
However, there are limitations worth highlighting. There was 
inconsistency in the case definition for BPD (Supplementary 
Table 4), and only 11 studies specified GA for infants included 
in the BPD and non-BPD groups. These could contribute to 
bias in any effectiveness assessment. The overall quality of the 
studies was only moderate, affected mainly by the presence of 
confounding factors, and most of the studies being retrospec-
tive and with low sample sizes. The effect of prematurity was 
not readily assessed for all the included outcomes in the meta-
analysis due to limited data with specified GA. We used the 
random-effects model for meta-analysis due to the assumed 
variation of the study parameters, and adjustments for zero-
events could affect the robustness of our model. Furthermore, 
there are limited data especially for population-level RSV hos-
pitalization rates, and, in addition, the data for the hospitaliza-
tion outcomes had significant heterogeneity (I2 of 97.1% and 
93.6%, respectively). The lack of data from lower income coun-
tries may also affect the generalizability of our results because 
these countries may have additional risk factors, which could 
have an impact on RSV disease burden.
CONCLUSIONS
Our results highlight a higher risk of severe RSV disease among 
infants with BPD compared with those without. The lack of 
standardized indication for prophylactic measures against se-
vere RSV disease in BPD and variations in the treatment and 
cost effectiveness of immunoprophylaxis may be due to the 
lack of standardized guidelines and BPD case definition, thus 
making their assessment difficult. Therefore, there is an urgent 
need to establish standardized BPD case definitions (and its 
subtypes), review and assess the guidelines for RSV prophylaxis 
and their indication, reconsider the recommendations for RSV 
immunoprophylaxis for BPD with possibility of including older 
children, and support the development of affordable vaccines 
and RSV-specific treatments.
Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
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